Healthcare Triangle's QuantumNexis Achieves Major Revenue Milestone Amid Global Expansion
Healthcare Triangle, Inc. (Nasdaq: HCTI), a frontrunner in digital transformation solutions tailored for healthcare and life sciences, has made headlines with its wholly-owned subsidiary, QuantumNexis. As of October 1, 2025, QuantumNexis reported that its Ezovion Electronic Medical Record (EMR) platform has facilitated over
$20 million in revenue, a testament to its vital role in helping healthcare providers transition to digital operations.
The Ezovion platform has emerged as a crucial digital infrastructure that supports hospitals, clinics, and specialized care providers across various markets. Through its advanced features, Ezovion not only digitizes healthcare operations but also streamlines workflows, ultimately enhancing patient outcomes. The positive response from healthcare providers indicates a solid trust in the platform's capabilities and promises a bright future.
Looking ahead, QuantumNexis is gearing up for a substantial global expansion, specifically targeting markets in
India,
Bangladesh,
Saudi Arabia, and
Malaysia. This strategic move is expected to drive the total processed revenue through the Ezovion platform up to an impressive
$37 million within the next six months. The anticipated growth reflects both the influx of new customers and the deeper engagement of current users who are progressively enlarging their digital infrastructures.
Words from Leadership
Suresh Venkatachari, Chairman of QuantumNexis, expressed enthusiasm about crossing the
$20 million threshold. He highlighted the confidence that healthcare providers have in Ezovion, suggesting that this milestone not only showcases existing demand but also sets the stage for robust future growth. “With our upcoming payment gateway, we expect to directly monetize this growth and tap into recurring revenue streams,” he stated.
In line with this, Healthcare Triangle’s Chief Operating Officer, Sujatha Ramesh, emphasized the importance of the payment gateway in transforming QuantumNexis’s business model. The platform operates on a consumption-based model, which allows it to grow alongside its customers, reinforcing long-term relationships and predictable demand.
Payment Gateway Launch
Adding to the momentum, QuantumNexis is set to introduce its integrated payment gateway, which marks a significant evolution in its revenue model. This gateway will provide the company with the opportunity to earn a 0.05% fee on every transaction processed through the platform, thus facilitating a direct and scalable revenue stream from the substantial transaction volume that flows through Ezovion.
Kasi Shanmugam, Head of Technology at QuantumNexis, elaborated that the gateway is designed with cutting-edge security features and scalability to support seamless integration of clinical and financial workflows. By embedding payment processing within clinical setups, QuantumNexis effectively removes friction for healthcare providers while capturing transaction-based revenue that automatically scales with platform growth.
Strategic Impact for Shareholders
These developments present multiple value growth drivers for Healthcare Triangle, including:
- - End-user revenue exceeding $20 million already processed through the Ezovion platform, highlighting solid market traction and adoption.
- - A projected increase to $37 million in end-user revenue within the next six months, supported by aggressive international expansion and enhanced customer engagement.
- - The impending launch of the integrated payment gateway, which will directly monetize transaction flows and create predictable recurring revenue streams for HCTI.
- - A strategic positioning as a hybrid SaaS and fintech company, creating a unique investment angle attractive to both healthcare technology and fintech-focused investors.
The initial deployments of the payment gateway are expected towards the end of
2025, with comprehensive scaling planned throughout
2026.
Healthcare Triangle's Chief Financial Officer, David Ayanoglou, concluded by mentioning,